Marker Therapeutics, Inc. (NASDAQ:MRKR) Financings

Marker Therapeutics, Inc.

Financings

RaiseDate
At-the-market programme of common stock
Tranche closed: US$10M raised
Use of proceeds: Extending the company's cash runway well into 2026
Nov 14, 2025
Private placement of common stock (or pre-funded warrants) and accompanying warrants
Announced: US$16.1M · US$3.2 a share · Warrants at US$4.03 for 60 months · Canaccord Genuity +1
Dealers: Canaccord Genuity (lead), Brookline Capital Markets, a division of Arcadia Securities, LLC
Buyers: Blue Owl Healthcare Opportunities; New Enterprise Associates (NEA); Aisling Capital
Use of proceeds: Support clinical advancement of the Phase 1 APOLLO study of MT-601 in lymphoma, among other uses
Dec 19, 2024

Read by 6ix AI from the company's releases